MEK
Mitogen-activated protein kinase kinase; MAPKK; MAP2K
MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs). The activated MAPK leads to the phosphorylation of downstream transcription factors that regulate various responses such as stress signaling, pathogen response, and hormone signaling.
In general, the MAPKKK phosphorylates a serine or threonine residue on a MAPKK, which sequentially activates a MAPK (ERK, p38 or JNK), the last protein in the cascade. Activation of the p38 MAPK occurs mainly through mitogen-activated protein kinase kinase 3 (MKK3) and MKK6 (sometimes MKK4). The JNK is regulated by two upstream MAP2Ks: MKK4 and MKK7. The highly homologous kinases, MEK1 and MEK2, act downstream of Ras and Raf to activate ERK mitogen-activated protein kinases.
MEK Isoform Specific Products
All Product Categories
-
MEK Related Products (250)
Related Products (250)
-
Antibodies (9)
-
MEK Isoform Comparison
-
Refametinib (Standard)
0 ImagesSynonyms: BAY 869766 (Standard); RDEA119 (Standard)Refametinib (Standard) is the analytical standard of Refametinib. This product is intended for research and analytical applications. Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
-
PD 198306 (Standard)
0 ImagesCat. No.: HY-107620RCAS No.: 212631-61-3PD 198306 (Standard) is the analytical standard of PD 198306 (HY-107620). This product is intended for research and analytical applications. PD 198306 is a selective MAPK/ERK-Kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects.
-
Trilinolein (Standard)
0 ImagesCat. No.: HY-128393RCAS No.: 537-40-6Trilinolein (Standard) is the analytical standard of Trilinolein (HY-128393). This product is intended for research and analytical applications. Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer.
-
Binimetinib-d3
0 ImagesCat. No.: HY-15202S1CAS No.: 2890696-59-8Synonyms: MEK162-d3; ARRY-162-d3; ARRY-438162-d3Binimetinib-d3 (MEK162-d3) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
-
Cobimetinib racemate (Standard)
0 ImagesSynonyms: GDC-0973 racemate (Standard); XL518 racemate (Standard)Cobimetinib (racemate) (Standard) is the analytical standard of Cobimetinib (racemate). This product is intended for research and analytical applications. Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor.
-
G-479
0 ImagesCat. No.: HY-120454CAS No.: 1168092-22-5G-479 is the inhibitor for MEK and hERG channel (IC50=14 μM). G-479 inhibits the proliferation of HCT-116 and A375 with IC50 of 0.049 μM and 0.004 μM. G-479 exhibits good metabolic stability in liver microsomes and good pharmacokinetic characteristics in rats.
-
Binimetinib (Standard)
0 ImagesSynonyms: MEK162 (Standard); ARRY-162 (Standard); ARRY-438162 (Standard)Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC50 of 12 nM.
-
Luvometinib-d
0 ImagesCat. No.: HY-159846SSynonyms: FCN-159-dLuvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.
-
MEK-IN-1
0 ImagesCat. No.: HY-U00312CAS No.: 870600-45-6MEK-IN-1 is a MEK inhibitor extracted from patent WO2008076415A1.
